APA (7th ed.) Citation

WH, S., S, C., JR, R., & A, A. (2004). Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis. Neurology, 63(11 Suppl 5), S19. https://doi.org/10.1212/wnl.63.11_suppl_5.s19

Chicago Style (17th ed.) Citation

WH, Stuart, Cohan S, Richert JR, and Achiron A. "Selecting a Disease-modifying Agent as Platform Therapy in the Long-term Management of Multiple Sclerosis." Neurology 63, no. 11 Suppl 5 (2004): S19. https://doi.org/10.1212/wnl.63.11_suppl_5.s19.

MLA (9th ed.) Citation

WH, Stuart, et al. "Selecting a Disease-modifying Agent as Platform Therapy in the Long-term Management of Multiple Sclerosis." Neurology, vol. 63, no. 11 Suppl 5, 2004, p. S19, https://doi.org/10.1212/wnl.63.11_suppl_5.s19.